Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I-Cheng Lee

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Journal of the Chinese Medical Association : JCMA|April 4, 2020
Gastrointestinal and liver manifestations in patients with COVID-19I-Cheng Lee, Teh-Ia Huo, Yi-Hsiang Huang
JHEP Reports : Innovation in Hepatology|August 21, 2025
Serum fibrosis marker M2BPGi-based novel score predicts survival of unresectable HCC undergoing immunotherapyPei-Chang Lee, Chi-Jung Wu, I-Cheng Lee, et al.
Radiology Case Reports|September 4, 2023
Percutaneous embolization of refractory biliocutaneous fistula following radiofrequency ablation: A case reportMei-Chen Chen, Hsuen-En Hwang, Nai-Chi Chiu, et al.
Journal of the Chinese Medical Association : JCMA|March 17, 2010
Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphomaI-Cheng Lee, Yi-Hsiang Huang, Chi-Jen Chu, et al.
Annals of the Rheumatic Diseases|June 30, 2021
Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic diseaseMing-Han Chen, I-Cheng Lee, Ming-Huang Chen, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|September 26, 2020
Prediction of survival according to kinetic changes of cytokines and hepatitis status following radioembolization with yttrium-90 microspheresChien-An Liu, I-Cheng Lee, Rheun-Chuan Lee, et al.
Journal for Immunotherapy of Cancer|September 1, 2020
Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinomaPei-Chang Lee, Yee Chao, Ming-Huang Chen, et al.
Plos One|October 15, 2013
CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot studyI-Cheng Lee, Yi-Hsiang Huang, Chien-Wei Su, et al.
International Journal of Cancer|June 11, 2013
Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatmentsI-Cheng Lee, Yi-Hsiang Huang, Gar-Yang Chau, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|December 18, 2020
Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapyChi-Jung Wu, Gar-Yang Chau, I-Cheng Lee, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Journal of the Chinese Medical Association : JCMA|April 4, 2020
Gastrointestinal and liver manifestations in patients with COVID-19I-Cheng Lee, Teh-Ia Huo, Yi-Hsiang Huang
JHEP Reports : Innovation in Hepatology|August 21, 2025
Serum fibrosis marker M2BPGi-based novel score predicts survival of unresectable HCC undergoing immunotherapyPei-Chang Lee, Chi-Jung Wu, I-Cheng Lee, et al.
Radiology Case Reports|September 4, 2023
Percutaneous embolization of refractory biliocutaneous fistula following radiofrequency ablation: A case reportMei-Chen Chen, Hsuen-En Hwang, Nai-Chi Chiu, et al.
Journal of the Chinese Medical Association : JCMA|March 17, 2010
Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphomaI-Cheng Lee, Yi-Hsiang Huang, Chi-Jen Chu, et al.
Annals of the Rheumatic Diseases|June 30, 2021
Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic diseaseMing-Han Chen, I-Cheng Lee, Ming-Huang Chen, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|September 26, 2020
Prediction of survival according to kinetic changes of cytokines and hepatitis status following radioembolization with yttrium-90 microspheresChien-An Liu, I-Cheng Lee, Rheun-Chuan Lee, et al.
Journal for Immunotherapy of Cancer|September 1, 2020
Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinomaPei-Chang Lee, Yee Chao, Ming-Huang Chen, et al.
Plos One|October 15, 2013
CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot studyI-Cheng Lee, Yi-Hsiang Huang, Chien-Wei Su, et al.
International Journal of Cancer|June 11, 2013
Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatmentsI-Cheng Lee, Yi-Hsiang Huang, Gar-Yang Chau, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|December 18, 2020
Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapyChi-Jung Wu, Gar-Yang Chau, I-Cheng Lee, et al.
Pageof 7